Announcements Trials
Browse Landscape

Phase

Phase 2 126Phase NA 110Phase 1 54Phase 3 29Phase 1/2 27Phase EARLY_PHASE1 10Phase 4 4Phase 2/3 3

Status

Completed 106Unknown 34Recruiting 30Terminated 23Active not recruiting 8Not yet recruiting 7Withdrawn 4Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 16Breast 12Tumor-Agnostic 5Thoracic 5Lymphoid 5Genitourinary 4CNS 4Plasma cell 3Other hematologic neoplasm 3Head & Neck 3Dermatologic 3Classical hematology 3Gynecologic 2Other 1NET 1Myeloid 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 2Prostatic Neoplasms 2

Interventions

bicalutamide 1Goserelin 15-aminolevulinic acid hexyl ester 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × Genitourinary × Clear all
NCT05568537 2025-01-03

Prostate MRI and Pylarify PSMA PET/CT

Corewell Health East

Phase 4 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT06390111 2024-11-22

ABLE-42

Ferring Pharmaceuticals

Phase 4 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT00785694 2015-04-24

Recurrence of Bladder Cancer After Transurethral Resection With Hexvix

GE Healthcare

Phase 4 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT00255268 2007-08-28

CMAB vs IMAB in Metastatic Prostate Cancer

AstraZeneca

Phase 4 Withdrawn
15 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡